Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

Market Cap	32.23B -15.3%
Revenue (ttm)	7.50B +12.2%
Net Income	1.66B +21.2%
EPS	14.80 +21.0%
Shares Out	111.98M
PE Ratio	19.45
Forward PE	n/a
Dividend	5.35 (1.86%)
Ex-Dividend Date	Jul 24, 2026

Volume	243,137
Open	291.00
Previous Close	288.10
Day's Range	286.45 - 291.85
52-Week Range	251.95 - 419.00
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2026

About NSE:ADVENZYMES

Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers serratiopeptidase, fungal lactase, peptizyme SP, nattokinase, fungal lipase, alpha galactosidase, saccharomyces boulardii, hemicellulose, papain, bromelain, fungal proteases, and bacterial alpha amylase. It also provides probiotics for human and animal nutrition. In addition, the company offers enzymes an...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1957
• Employees: 409
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ADVENZYMES

Financial Performance

In fiscal year 2026, NSE:ADVENZYMES's revenue was 7.46 billion, an increase of 17.09% compared to the previous year's 6.37 billion. Earnings were 1.69 billion, an increase of 28.68%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error